Overview

68Ga-NOTA-RM26 PET/CT for the Detection of Gastrointestinal Stromal Tumor

Status:
Recruiting

Trial end date:
2022-08-31

Target enrollment:
0

Participant gender:
All

Summary

This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the diagnostic performance and evaluation efficacy of 68Ga-NOTA-RM26 in Gastrointestinal stromal tumor（GIST）patients. A single dose of 55.5 to 148 MBq(1.5-4 mCi) of 68Ga-NOTA-RM26 will be injected intravenously. Patients underwent whole-body PET/CT scans at 30-90 minutes after intravenous injection.

Phase:

Early Phase 1

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Peking Union Medical College Hospital

Treatments:

68Ga-NOTA-RM26

Criteria

Inclusion Criteria:

- Patients in suspicion of gastrointestinal stromal tumors by CT or ultrasonography,and
being able to provide basic information and sign the written informed consent form.

Exclusion Criteria:

- The exclusion criteria included claustrophobia, pregnancy, breastfeeding, kidney or
liver failure, inability to fulfill the study, and undergoing any preceding local or
systemic therapies that might interfere with GRPR binding.